Blue lacy matrix in giant cell tumour of bone with or without denosumab therapy

[1]  Y. Oda,et al.  Histological and immunohistochemical features and genetic alterations in the malignant progression of giant cell tumor of bone: a possible association with TP53 mutation and loss of H3K27 trimethylation , 2021, Modern Pathology.

[2]  T. Shibata,et al.  Absence of H3F3A mutation in a subset of malignant giant cell tumor of bone , 2019, Modern Pathology.

[3]  H. Yoshikawa,et al.  Clinical outcome of primary giant cell tumor of bone after curettage with or without perioperative denosumab in Japan: from a questionnaire for JCOG 1610 study , 2018, World Journal of Surgical Oncology.

[4]  K. Ohashi,et al.  Giant cell tumours of bone treated with denosumab: histological, immunohistochemical and H3F3A mutation analyses , 2018, Histopathology.

[5]  Y. Oda,et al.  Diagnostic utility of histone H3.3 G34W, G34R, and G34V mutant-specific antibodies for giant cell tumors of bone. , 2017, Human pathology.

[6]  A. Franchi,et al.  Histone 3.3 mutations in giant cell tumor and giant cell-rich sarcomas of bone. , 2017, Human pathology.

[7]  Sakae Tanaka,et al.  Highly recurrent H3F3A mutations with additional epigenetic regulator alterations in giant cell tumor of bone , 2017, Genes, chromosomes & cancer.

[8]  T. Barth,et al.  H3F3A mutation in giant cell tumour of the bone is detected by immunohistochemistry using a monoclonal antibody against the G34W mutated site of the histone H3.3 variant , 2017, Histopathology.

[9]  A. Flanagan,et al.  The H3F3 K36M mutant antibody is a sensitive and specific marker for the diagnosis of chondroblastoma , 2016, Histopathology.

[10]  M. Stratton,et al.  Distinct H3F3A and H3F3B driver mutations define chondroblastoma and giant cell tumor of bone , 2013, Nature Genetics.